Noel W Clarke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1329855/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. Journal of Clinical Oncology, 2022, 40, 825-836.	1.6	40
2	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, The, 2022, 399, 447-460.	13.7	173
3	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5â€year followâ€up results from the STAMPEDE randomised trial (NCT00268476). International Journal of Cancer, 2022, 151, 422-434.	5.1	29
4	Interventions for obstructive uropathy in advanced prostate cancer: a populationâ€based study. BJU International, 2022, , .	2.5	1
5	Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. PLoS ONE, 2022, 17, e0269192.	2.5	4
6	Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, 1, .		124
7	Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial Journal of Clinical Oncology, 2022, 40, 5019-5019.	1.6	2
8	Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial Journal of Clinical Oncology, 2022, 40, 5050-5050.	1.6	1
9	Maintaining a safe uro-oncological surgical service in the face of the COVID-19 pandemic. Journal of Clinical Urology, 2021, 14, 404-409.	0.1	1
10	Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. Lancet, The, 2021, 397, 581-591.	13.7	17
11	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation, 2021, 144, 1295-1307.	1.6	75
12	Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. European Urology, 2021, 80, 522-523.	1.9	5
13	Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. JCO Precision Oncology, 2020, 4, 882-897.	3.0	22
14	The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1 RT Comparison― European Urology Oncology, 2020, 3, 412-419.	5.4	9
15	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	1.9	278
16	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer. JACC: CardioOncology, 2020, 2, 70-81.	4.0	30
17	Diagnosis, Staging and Management of Testis Cancer. , 2020, , 639-652.		0
18	Importance of nonâ€regional lymph nodes in assigning risk in primary metastatic prostate cancer. BJU International, 2019, 123, 65-73.	2.5	13

#	Article	IF	CITATIONS
19	The management of testis cancer. Surgery, 2019, 37, 513-523.	0.3	1
20	Abiraterone in "High-―and "Low-risk―Metastatic Hormone-sensitive Prostate Cancer. European Urology, 2019, 76, 719-728.	1.9	142
21	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 809-818.	0.8	23
22	This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. Trials, 2019, 20, 264.	1.6	42
23	Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. European Urology, 2019, 76, 115-124.	1.9	203
24	Prostate radiotherapy in newly diagnosed metastatic prostate cancer. Current Opinion in Urology, 2019, 29, 620-628.	1.8	4
25	Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. European Urology Oncology, 2019, 2, 1-11.	5.4	27
26	Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer. European Urology Focus, 2019, 5, 831-841.	3.1	11
27	Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. BJU International, 2018, 121, 680-683.	2.5	15
28	Magnetic Resonance Imaging and Detection of Metastases in Prostate Cancer: Learning Lessons from History. European Urology, 2018, 73, 92-93.	1.9	0
29	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	1.9	488
30	Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer. Cell Reports, 2018, 25, 3504-3518.e6.	6.4	70
31	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, The, 2018, 392, 2353-2366.	13.7	901
32	Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study. Radiotherapy and Oncology, 2018, 128, 357-363.	0.6	9
33	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. New England Journal of Medicine, 2017, 377, 338-351.	27.0	1,315
34	Infrared spectral histopathology using haematoxylin and eosin (H&E) stained glass slides: a major step forward towards clinical translation. Analyst, The, 2017, 142, 1258-1268.	3.5	38
35	Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: AÂsystematic review and meta-analysis. European Journal of Cancer, 2017, 84, 88-101.	2.8	128
36	Adding Celecoxib With or Without Zoledronic Acid for Hormone-NaÃ ⁻ ve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of Clinical Oncology, 2017, 35, 1530-1541.	1.6	54

#	Article	IF	CITATIONS
37	Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy. BJU International, 2016, 117, 249-252.	2.5	42
38	High-throughput quantum cascade laser (QCL) spectral histopathology: a practical approach towards clinical translation. Faraday Discussions, 2016, 187, 135-154.	3.2	46
39	The management of testis cancer. Surgery, 2016, 34, 517-526.	0.3	1
40	Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer. European Urology Focus, 2016, 2, 276-283.	3.1	2
41	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, The, 2016, 387, 1163-1177.	13.7	1,570
42	Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncology, The, 2016, 17, 243-256.	10.7	361
43	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer. JAMA Oncology, 2016, 2, 348.	7.1	155
44	External urethral sphincter electromyography in asymptomatic women and the influence of the menstrual cycle. BJU International, 2015, 116, 423-431.	2.5	18
45	Implementing newer agents for the management of castrateâ€resistant prostate cancer: what is known and what is needed?. BJU International, 2015, 115, 364-372.	2.5	8
46	Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 464-475.	1.6	32
47	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era― Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European Urology, 2015, 67, 1028-1038.	1.9	340
48	Quantification of skeletal metastases in castrateâ€resistant prostate cancer predicts progressionâ€free and overall survival. BJU International, 2014, 114, E70-E73.	2.5	30
49	Advanced prostate cancer: advancing patient care. Trends in Urology & Men's Health, 2014, 5, 40-42.	0.4	0
50	Should centralized histopathological review in penile cancer be the global standard?. BJU International, 2014, 114, 340-343.	2.5	22
51	Automated high-throughput assessment of prostate biopsy tissue using infrared spectroscopic chemical imaging. Proceedings of SPIE, 2014, , .	0.8	8
52	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. European Urology, 2014, 66, 799-802.	1.9	56
53	The <scp>M</scp> elbourne Consensus Statement on the early detection of prostate cancer. BJU International, 2014, 113, 186-188.	2.5	64
54	Assessment of paraffin removal from prostate FFPE sections using transmission mode FTIR-FPA imaging. Analytical Methods, 2014, 6, 1028-1035.	2.7	45

#	Article	IF	CITATIONS
55	Assessing the challenges of Fourier transform infrared spectroscopic analysis of blood serum. Journal of Biophotonics, 2014, 7, 180-188.	2.3	57
56	Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. BMC Cancer, 2014, 14, 226.	2.6	13
57	Balancing Toxicity and Efficacy: Learning from Trials and Treatment Using Antiresorptive Therapy in Prostate Cancer. European Urology, 2014, 65, 287-288.	1.9	3
58	Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clinical Epigenetics, 2013, 5, 16.	4.1	33
59	Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PRO9). Lancet Oncology, The, 2013, 14, 306-316.	10.7	83
60	Whole organ cross-section chemical imaging using label-free mega-mosaic FTIR microscopy. Analyst, The, 2013, 138, 7066.	3.5	24
61	FTIR microspectroscopy of selected rare diverse subâ€variants of carcinoma of the urinary bladder. Journal of Biophotonics, 2013, 6, 73-87.	2.3	38
62	Management of testicular tumours. Surgery, 2013, 31, 535-542.	0.3	0
63	Coming Up for Air: Follow-up and Risk Stratification After Negative Prostate Cancer Screening. European Urology, 2013, 63, 634-635.	1.9	1
64	Prostate radiotherapy for men with metastatic disease: a new comparison in the <scp>S</scp> ystemic <scp>T</scp> herapy in <scp>A</scp> dvancing or <scp>M</scp> etastatic <scp>P</scp> rostate <scp>C</scp> ancer: <scp>E</scp> valuation of <scp>D</scp> rug <scp>E</scp> fficacy (<scp>STAMPEDE</scp>) trial. BlU International, 2013, 111, 697-699.	2.5	28
65	Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. Endocrine-Related Cancer, 2013, 20, 137-149.	3.1	36
66	<scp>UBE</scp> 2 <scp>QL</scp> 1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene. Human Mutation, 2013, 34, 1650-1661.	2.5	18
67	Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncology, The, 2012, 13, 549-558.	10.7	100
68	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2012, 62, 523-533.	1.9	214
69	FTIR microscopy of biological cells and tissue: data analysis using resonant Mie scattering (RMieS) EMSC algorithm. Analyst, The, 2012, 137, 1370.	3.5	117
70	Copper Modulates Zinc Metalloproteinase-Dependent Ectodomain Shedding of Key Signaling and Adhesion Proteins and Promotes the Invasion of Prostate Cancer Epithelial Cells. Molecular Cancer Research, 2012, 10, 1282-1293.	3.4	19
71	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials, 2012, 13, 168.	1.6	121
72	Landmarks in nonâ€hormonal pharmacological therapies for castrationâ€resistant prostate cancer. BJU International, 2012, 110, 14-22.	2.5	8

#	Article	IF	CITATIONS
73	Should All Patients Receive Statins to Reduce Cancer Risk After Heart Transplantation?. Circulation, 2012, 126, 391-391.	1.6	1
74	Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics, 2012, 7, 278-290.	2.7	54
75	Flexible trial design in practice: Dropping and adding arms in STAMPEDE (MRC PR08, CRUK/06/019)—A multiarm, multistage randomized controlled trial Journal of Clinical Oncology, 2012, 30, 27-27.	1.6	1
76	Early prostate cancer – which treatment do men prefer and why?. BJU International, 2011, 107, 1762-1768.	2.5	73
77	Reflections on attempted Anglo–Japanese collaboration on STAMPEDE: A randomized controlled trial for men with prostate cancer. International Journal of Urology, 2011, 18, 553-554.	1.0	3
78	Is Population Screening for Prostate Cancer Good or Bad?. European Urology, 2011, 59, 363-364.	1.9	1
79	Targeted Caval Cytoreduction: Solid Foundations or Shifting Sands?. European Urology, 2011, 59, 919-920.	1.9	1
80	Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. Trials, 2011, 12, .	1.6	10
81	Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2011, 29, 733-738.	1.6	155
82	Management of testicular tumours. Surgery, 2010, 28, 610-616.	0.3	0
83	The Motion: GnRH Antagonists are the New Way Forward in Hormonal Therapy. European Urology, 2010, 57, 534-537.	1.9	2
84	Differential Complication Rates Following Radical Cystectomy in the Irradiated and Nonirradiated Pelvis. European Urology, 2010, 57, 1058-1063.	1.9	50
85	Re: Umberto Capitanio, Shahrokh F. Shariat, Hendrik Isbarn, et al. Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. Eur Urol 2009;56:1–9. European Urology, 2010, 57, e34-e35.	1.9	0
86	RMieSâ€EMSC correction for infrared spectra of biological cells: Extension using full Mie theory and GPU computing. Journal of Biophotonics, 2010, 3, 609-620.	2.3	116
87	Resonant Mie Scattering (RMieS) correction of infrared spectra from highly scattering biological samples. Analyst, The, 2010, 135, 268-277.	3.5	332
88	When Should Radiotherapy Be Used after Radical Prostatectomy? The RADICALS-RT Trial. British Journal of Medical and Surgical Urology, 2010, 3, 190-193.	0.2	5
89	Imaging angiogenesis of genitourinary tumors. Nature Reviews Urology, 2010, 7, 69-82.	3.8	27
90	SR-FTIR spectroscopy of renal epithelial carcinoma side population cells displaying stem cell-like characteristics. Analyst, The, 2010, 135, 3133.	3.5	44

#	Article	IF	CITATIONS
91	Hoechst 33342 Side Population Identification Is a Conserved and Unified Mechanism in Urological Cancers. Stem Cells and Development, 2009, 18, 1515-1522.	2.1	67
92	Should 5α-reductase inhibitors be used for prostate disease?. Nature Reviews Urology, 2009, 6, 358-359.	3.8	1
93	Classification of fixed urological cells using Raman tweezers. Journal of Biophotonics, 2009, 2, 47-69.	2.3	58
94	Investigating FTIR based histopathology for the diagnosis of prostate cancer. Journal of Biophotonics, 2009, 2, 104-113.	2.3	97
95	Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials, 2009, 10, 39.	1.6	120
96	Molecular mechanisms of metastasis in prostate cancer. Asian Journal of Andrology, 2009, 11, 57-67.	1.6	78
97	Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multiâ€arm, multistage randomized controlled trial. BJU International, 2009, 103, 464-469.	2.5	86
98	CD133: A MARKER OF TRANSIT AMPLIFICATION RATHER THAN STEM CELL PHENOTYPE IN THE PROSTATE?. BJU International, 2009, 103, 856-858.	2.5	8
99	A contemporary standard for morbidity and outcome after radical cystectomy. BJU International, 2009, 104, 628-632.	2.5	25
100	Abarelix and other gonadotrophinâ€releasing hormone antagonists in prostate cancer. BJU International, 2009, 104, 1580-1584.	2.5	24
101	Response to Letter to the Editor: National Re-Audit of Urology Outpatient Practice in the UK. British Journal of Medical and Surgical Urology, 2009, 2, 263-263.	0.2	0
102	CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Molecular Cancer, 2009, 8, 31.	19.2	65
103	Male adnexal tumour of wolffian origin: The first report of metastatic disease. Scandinavian Journal of Urology and Nephrology, 2009, 43, 253-256.	1.4	5
104	Reflection contributions to the dispersion artefact in FTIR spectra of single biological cells. Analyst, The, 2009, 134, 1171.	3.5	118
105	Management of the Spectrum of Hormone Refractory Prostate Cancer(EAU Lecture,The 97th Annual) Tj ETQq1 1	0,784314	l rgBT /Overle
106	The Biology of Bone Metastases from Prostate Cancer and the Role of Bisphosphonates. , 2008, , 253-281.		3
107	Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as firstâ€line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU International, 2008, 102, 442-445.	2.5	41
108	Aetiology, diagnosis and management of urothelial tumours of the renal pelvis and ureter. BJU International, 2008, 102, 1302-1306.	2.5	9

#	Article	IF	CITATIONS
109	Editorial Comment on: Noninvasive Detection of Testicular Carcinoma In Situ in Semen Using OCT3/4. European Urology, 2008, 54, 159-160.	1.9	0
110	The Motion: All Men Over the Age of 50 Should be Encouraged to Take a 5α-Reductase Inhibitor to Prevent Prostate Cancer. European Urology, 2008, 53, 1079-1083.	1.9	2
111	Measurement of elastic properties of prostate cancer cells using AFM. Analyst, The, 2008, 133, 1498.	3.5	247
112	Spectral discrimination of live prostate and bladder cancer cell lines using Raman optical tweezers. Journal of Biomedical Optics, 2008, 13, 064004.	2.6	71
113	Late tissue effects following radiotherapy and neoadjuvant hormone therapy of the prostate measured with quantitative magnetic resonance imaging. Radiotherapy and Oncology, 2008, 88, 127-134.	0.6	26
114	What Does Failure After Surgery or Radiation Mean?. European Urology Supplements, 2008, 7, 410-415.	0.1	4
115	Discrimination of prostate cancer cells and non-malignant cells using secondary ion mass spectrometry. Analyst, The, 2008, 133, 175-179.	3.5	27
116	Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. American Journal of Physiology - Renal Physiology, 2008, 295, F680-F687.	2.7	76
117	Complications Arising in the Final Year of Life in Men Dying from Advanced Prostate Cancer. Journal of Palliative Medicine, 2007, 10, 705-711.	1.1	43
118	Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. Journal of Lipid Research, 2007, 48, 1846-1856.	4.2	133
119	Discrimination of prostate cancer cells by reflection mode FTIR photoacoustic spectroscopy. Analyst, The, 2007, 132, 292.	3.5	45
120	Optical artefacts in transflection mode FTIR microspectroscopic images of single cells on a biological support: the effect of back-scattering into collection optics. Analyst, The, 2007, 132, 750.	3.5	48
121	Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate, 2007, 67, 1384-1396.	2.3	102
122	Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU International, 2007, 99, 1376-1379.	2.5	130
123	Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunology, Immunotherapy, 2007, 56, 1743-1753.	4.2	177
124	Skeletal Preservation in Prostate Cancer: The Changing Role of the Urologist. European Urology Supplements, 2006, 5, 871-872.	0.1	2
125	New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer. European Urology Supplements, 2006, 5, 880-885.	0.1	2
126	New Clinical Tools for Urologists: Treatment of Bone Loss. European Urology Supplements, 2006, 5, 877-879.	0.1	0

#	Article	IF	CITATIONS
127	Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis. European Urology Supplements, 2006, 5, 873-876.	0.1	3
128	The Natural History of Postoperative Renal Function in Patients Undergoing Ileal Conduit Diversion for Cancer Measured Using Serial Isotopic Glomerular Filtration Rate and 99m Technetium-Mercaptoacetyltriglycine Renography. Journal of Urology, 2006, 176, 2518-2522.	0.4	41
129	Urine telomerase activity for the diagnosis of bladder cancer. Nature Reviews Urology, 2006, 3, 192-193.	1.4	Ο
130	The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK. BJU International, 2006, 97, 266-269.	2.5	22
131	Natural History and Treatment of Bone Complications in Prostate Cancer. European Urology, 2006, 49, 429-440.	1.9	78
132	A Correlation of FTIR Spectra Derived from Prostate Cancer Biopsies with Gleason Grade and Tumour Stage. European Urology, 2006, 50, 750-761.	1.9	111
133	Management of the Spectrum of Hormone Refractory Prostate Cancer. European Urology, 2006, 50, 428-439.	1.9	43
134	The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer. European Urology, 2006, 50, 873-878.	1.9	2
135	Management of testicular tumours. Surgery, 2006, 24, 163-168.	0.3	0
136	Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. International Journal of Radiation Oncology Biology Physics, 2005, 61, 420-425.	0.8	57
137	Male adnexal tumour of probable Wolffian duct origin. Scandinavian Journal of Urology and Nephrology, 2005, 39, 520-522.	1.4	4
138	The molecular staging of prostate cancer. BJU International, 2004, 94, 1217-1220.	2.5	4
139	Differential Inhibition of Invasion and Proliferation by Bisphosphonates: Anti-Metastatic Potential of Zoledronic Acid in Prostate Cancer. European Urology, 2004, 46, 389-402.	1.9	47
140	The combined application of FTIR microspectroscopy and ToF-SIMS imaging in the study of prostate cancer. Faraday Discussions, 2004, 126, 41.	3.2	78
141	Novel method for the isolation and characterisation of the putative prostatic stem cell. Cytometry, 2003, 54A, 89-99.	1.8	97
142	The Biology and Treatment of Bone Metastases in Prostate Cancer. , 2003, , 931-956.		0
143	A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. International Journal of Cancer, 2002, 101, 454-460.	5.1	84
144	Molecular prediction of progression in patients with conservatively managed prostate cancer. Urology, 2001, 58, 762-766.	1.0	12

#	Article	IF	CITATIONS
145	Scatter factor influences the formation of prostate epithelial cell colonies on bone marrow stroma in vitro. Clinical and Experimental Metastasis, 1999, 17, 331-338.	3.3	24
146	Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. , 1998, 34, 203-213.		38
147	Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. Clinical and Experimental Metastasis, 1997, 15, 218-227.	3.3	49
148	The Effects of Orchidectomy on Skeletal Metabolism in Metastatic Prostate Cancer. Scandinavian Journal of Urology and Nephrology, 1993, 27, 475-483.	1.4	37